A research team at The University of Texas have revealed that two critical characteristics of breast cancer that are important to treatment can be identified by measuring gene expression in the tumour
Researchers developed and validated a new genomic micro array test that identifies whether a tumour’s growth is fuelled by the female hormone estrogen and the role of a growth factor receptor known as HER-2 that makes a tumour vulnerable to a specific drug. The status of these factors is now determined by pathology tests.
"This is one important step towards personalized diagnosis and treatment planning based on an integrated genomic test of an individual tumor," said senior author W. Fraser Symmans, M.D., associate professor in the M. D. Anderson Department of Pathology.
The Lancet Oncology paper results are the latest in an effort by the research team to develop a single test to quickly and efficiently determine the characteristics and vulnerabilities of a patient's breast cancer and ultimately to guide treatment.
About 70 percent of breast cancers are estrogen-receptor positive and another 15 to 25 percent are human epidermal growth factor receptor-2 (HER-2) positive. Each receptor status requires different types of treatment.
The gene expression tests were 90 percent accurate for both receptors, which makes them comparable to, if not better than, existing pathology tests.
"This moves us closer to developing an integrated single genomic test that could estimate the risk of cancer relapse after surgery, determine the ER and HER2 receptor status, and also gauge the sensitivity of the tumor to hormone therapy and chemotherapy," says Lajos Pusztai, M.D., Ph.D., associate professor in the M. D. Anderson Department of Breast Medical Oncology, and team leader with Symmans.
ER-positive tumors are treated with estrogen-suppressing drugs such as Tamoxifen. Tumors that are HER-2 positive are sensitive to Herceptin, an antibody-based drug that binds to the HER-2 receptors, blocking them from coupling with growth factors that fuel breast cancer.
Last fall, the group published a study showing that a genomic microarray test can also predict a patient's response to chemotherapy. They also presented a paper in December showing that another genomic index predicts how an ER-positive patient will respond to hormonal therapy.
A prospective clinical trial will soon open at M. D. Anderson to use these tests to recommend treatment for patients with newly diagnosed stage I-III breast cancer.
In the Lancet Oncology paper, they employed an Affymetrix microarray to gather estrogen receptor and HER-2 receptor gene expression data from 495 breast cancer samples from seven institutions. The samples included both fine needle aspiration biopsies and traditional biopsies.
The team used 195 fine-needle biopsy samples to set gene expression thresholds that predicted ER-positive status with 90 percent accuracy and HER-2-positive status with 93 percent accuracy. They then applied those thresholds to two more validation studies involving the remaining samples, which showed that the initial results were both reliable and reproducible.
The gene expression tests disagreed with traditional immunohistochemical lab analysis of the tumors by 8 percent for ER and 11 percent for HER-2. The researchers note this degree of discrepancy is usual when different diagnostic methods are applied to the same samples.